This article was originally published in The Rose Sheet
Executive SummaryScent and Care division revenues increased 6.5% on a local-currency basis to $1.03 bil. in 2007, the fragrance and flavor company announces March 5. The performance of the business was boosted by 10.6% growth in cosmetics and 8.5% local currency growth rate in fine fragrances based on "winning some major prestigious new fragrances in 2007," firm says. Symrise achieved net sales growth of 6.7% to $1.96 bil. in fiscal 2007 based on its concentration on fast-growing regions and business segments, German firm notes. Symrise is poised to maintain 5%-6% sales growth per year in 2008 and 2009, the company maintains...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.